Press releases

Suspending the medical device tax will allow the industry to reinvest in work to benefit patients

Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation

Boston Scientific will webcast its conference call discussing Q4 financial results and business highlights on Feb. 1, 2018 at the updated time of 7:30 a.m. EST.

Randomized controlled trial demonstrates effectiveness of long-term treatment with sub-perception spinal cord stimulation

System offers non-opioid treatment option with multiple therapies for people with chronic pain

Based upon preliminary unaudited financial information, the company generated approximately $2.41 billion in sales during Q4 2017.

Boston Scientific will participate in the upcoming healthcare conference on Jan. 9, 2018. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare conference on Jan. 4, 2018. A live webcast and replay will be available.

DBS platform offers physicians advanced technology to treat symptoms of Parkinson's disease

Boston Scientific will participate in the healthcare conference on December 14, 2017. A live webcast and replay will be available.

Company announces delay for commercialization of the LOTUS Edge™ Aortic Valve System in Europe and the U.S.

Boston Scientific will participate in the healthcare conference on December 7, 2017. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare conference on Nov. 28, 2017. A live webcast and replay will be available.

American Heart Association, American College of Cardiology and Heart Rhythm Society issue updated guidelines underscoring benefits of the S-ICD system

Boston Scientific will participate in the Stifel 2017 Healthcare Conference on November 14, 2017.

Boston Scientific will participate in the conference on November 7, 2017.

Late-breaking data presented at TCT 2017 with simultaneous publication in the Journal of the American College of Cardiology

“We continue to invest in a deep and innovative portfolio and expand into faster-growing markets," said CEO Mike Mahoney.

Key data presented will include five-year outcomes for the WATCHMAN device as an alternative to long-term warfarin therapy for patients with non-valvular Afib.

CEO Mike Mahoney welcomed Ralls-Morrison as “an accomplished leader with deep expertise in broad-ranging legal matters and enterprise business strategy.”

Acquisition to strengthen company's electrophysiology portfolio

Company will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2017.

HeartLogic is the first and only heart failure diagnostic in an implantable device shown to provide weeks of advance notice of an impending heart failure event.

Data presented demonstrate alert improves heart failure risk prediction

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

Boston Scientific will participate in the Morgan Stanley healthcare conference on Sept. 12, 2017. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 7, 2017. Learn how to watch the webcast or replay.

Boston Scientific will participate in the investor conference on August 9, 2017. Learn how to watch the webcast or replay.

"Our strong financial performance in the first half of 2017 reflects our innovative portfolio,” said CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results for Q2 ended June 30, 2017. Learn how to tune in or watch the replay.

Investor meeting will cover Boston Scientific’s business and long-term growth strategies, including by expanding category leadership and driving global growth.

Industry's first MR-conditional directional DBS System with stimulation visualization

Results from evaluation of real-world patients presented at American Thoracic Society International Conference

Boston Scientific will participate in the healthcare conference on May 23, 2017. Learn how to watch the webcast or replay.

The first head-to-head pivotal study comparing two different TAVI platforms demonstrated the LOTUS™ Valve System’s superior efficacy.

BAcquisition expands company's structural heart portfolio; increases offerings for the treatment of patients with valvular heart disease

Largest prospective study of the WATCHMAN device presented as late-breaking trial at Heart Rhythm 2017

Analyses evaluated the impact of ethnicity, gender and income on cardiovascular outcomes

Late-breaker data presented at Heart Rhythm 2017

Pivotal data from REPRISE III and EWOLUTION among four late-breaking clinical trials to be presented

New devices combine longest-lasting battery technology, therapy optimization and HeartLogic™ heart failure diagnostics

Late-breaking clinical trials feature subcutaneous implantable defibrillator (S-ICD) and WATCHMAN™ left atrial appendage closure device

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...

"We are pleased with our performance in the first quarter,” said CEO Mike Mahoney

MADIT S-ICD trial to study EMBLEM™ MRI S-ICD System; part of pilot initiative to increase percentage of females enrolled in clinical studies

Boston Scientific will webcast both its Investor Day meeting and its conference call with financial results for Q1 ended March 31, 2017. Learn how to tune in.

Acquisition will expand treatments for patients with valvular heart disease and strengthen company's position in structural heart globally

Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; potential for significant cost savings

Edwards found to infringe on Boston Scientific patents in Germany and U.K.

Boston Scientific will participate in the healthcare conference on March 15, 2017. A live webcast and replay will be available.

Top winners will be awarded up to $50,000 of in-kind support to advance submitted concept

Boston Scientific will participate in the healthcare investor conference on March 7, 2017. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare investor conference on Feb. 23, 2017. A live webcast and replay will be available.

"Boston Scientific delivered excellent financial results in 2016,” said CEO Mike Mahoney

Boston Scientific will participate in the healthcare investor conference on Feb. 15, 2017. A live webcast and replay will be available.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 ended Dec. 31, 2016. Learn how to tune in.

Boston Scientific will participate in the J.P. Morgan Healthcare Conference on January 10, 2017. A live webcast and replay will be available.

Acquisition will bring manufacturing assets and biologic tissue capabilities for use in Boston Scientific heart valve technologies.

Third consecutive “Best Places to Work for LGBT Equality” award

$75M transaction enhances manufacturing expertise in structural heart

Boston Scientific will participate in the healthcare conference on December 7, 2016. A live webcast and replay will be available.

Acquisition expands Boston Scientific endoscopy portfolio with a comprehensive array of gastrointestinal services and devices

Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing from the Shingo Institute, part of the Jon M....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 28th Annual Piper Jaffray Healthcare Conference on November 29 in New York City. Jeff Mirviss, senior vice president &...

Boston Scientific (NYSE: BSX) today announced results from the first clinical trial evaluating the performance of the HeartLogic™ Heart Failure Diagnostic Service to predict impending heart...

Boston Scientific (NYSE: BSX) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio...

MARLBOROUGH, Mass., (Nov. 8, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the Dakota™ Nitinol Stone Retrieval Device with OpenSure™...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has extended its previously announced tender offer for all shares of...

Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue...

Boston Scientific (NYSE: BSX) announced initial U.S. commercial performance results of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial...

As part of the commitment to support health equity for all patients, Boston Scientific Corporation (NYSE: BSX) sponsored the PLATINUM Diversity study to evaluate the clinical outcomes of the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel 2016 Healthcare Conference on November 15 in New York City. Dan Brennan, executive vice president & chief...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of $2.035 to...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Credit Suisse Healthcare Conference on November 7, in Scottsdale, Arizona. Joe Fitzgerald, executive vice...

Boston Scientific (NYSE: BSX) today announced key data which will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Marlborough, Mass. October 13, 2016) -- Boston Scientific Corporation (NYSE: BSX) today announced a worldwide call for submissions to the second annual Boston Scientific Connected Patient...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain

CEO Mike Mahoney welcomes Fujimori as a business leader with “significant insights on how large companies plan, execute and compete globally.”

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2016. Learn how to tune in.

Studies show that treatment is less costly and has lower hospital re-admissions

Accelerates momentum to bring differentiated value to patients and health care systems

Boston Scientific will participate in the healthcare conference on June 9, 2016. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare investor conference on June 7, 2016. A live webcast and replay will be available.

Full-body MRI access expands spinal cord stimulation offering and brings customized therapy to more patients suffering from chronic pain

Key data to be presented include real-world outcomes with the with the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device in Europe

Late-breaker data presented at HRS scientific sessions is most extensive post-market study for S-ICD

New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System

Boston Scientific will participate in the healthcare investor conference on May 12, 2016. A live webcast and replay will be available.

Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS)...